A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK

por Zimovetz, Evelina A., Joseph, Alain, Ayyagari, Rajeev, Mauskopf, Josephine A.
Publicado 2017

Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review

por Zimovetz, Evelina A, Wolowacz, Sorrel E, Classi, Peter M, Birt, Julie
Publicado 2012

A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to...

por Zimovetz, Evelina A., Beard, Stephen M., Hodgkins, Paul, Bischof, Matthias, Mauskopf, Josephine A., Setyawan, Juliana
Publicado 2016

Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review

por Copley-Merriman, Catherine, Stevinson, Kendall, Liu, Frank Xiaoqing, Wang, Jingshu, Mauskopf, Josephine, Zimovetz, Evelina A., Chmielowski, Bartosz
Publicado 2018